Chemistry:Vobarilizumab

From HandWiki
Revision as of 01:59, 6 February 2024 by StanislovAI (talk | contribs) (link)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Monoclonal antibody
Vobarilizumab
Monoclonal antibody
TypeSingle-chain variable fragment
SourceHumanized
TargetIL6R
Clinical data
Other namesALX0061
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC1118H1757N315O364S8
Molar mass25691.68 g·mol−1

Vobarilizumab (INN; development code ALX0061) is a humanized bispecific nanobody (Llama-derived heavy-chain only (Vhh) antibody) designed for the treatment of inflammatory autoimmune diseases.[1][2][3]

This drug was developed by Ablynx NV to block interleukin-6 receptor. Vobarilizumab has been evaluated in patients with rheumatoid arthritis[4] as well as in lupus.[5]

References